Literature DB >> 25808270

Drug Distribution to Human Tissues: Prediction and Examination of the Basic Assumption in In Vivo Pharmacokinetics-Pharmacodynamics (PK/PD) Research.

Patrick Poulin1.   

Abstract

The tissue:plasma partition coefficients (Kp ) are good indicators of the extent of tissue distribution. Therefore, advanced tissue composition-based models were used to predict the Kp values of drugs under in vivo conditions on the basis of in vitro and physiological input data. These models, however, focus on animal tissues and do not challenge the predictions with human tissues for drugs. The first objective of this study was to predict the experimentally determined Kp values of seven human tissues for 26 drugs. In all, 95% of the predicted Kp values are within 2.5-fold error of the observed values in humans. Accordingly, these results suggest that the tissue composition-based model used in this study is able to provide accurate estimates of drug partitioning in the studied human tissues. Furthermore, as the Kp equals to the ratio of total concentration between tissue and plasma, or the ratio of unbound fraction between plasma (fup ) and tissue (fut ), this parameter Kp would deviate from the unity. Therefore, the second objective was to examine the corresponding relationships between fup and fut values experimentally determined in humans for several drugs. The results also indicate that fup may significantly deviate to fut ; the discrepancies are governed by the dissimilarities in the binding and ionization on both sides of the membrane, which were captured by the tissue composition-based model. Hence, this violated the basic assumption in in vivo pharmacokinetics-pharmacodynamics (PK/PD) research, since the free drug concentration in tissue and plasma was not equal particularly for the ionizable drugs due to the pH gradient effect on the fraction of unionized drug in plasma (fuip ) and tissue (fuit ) (i.e., fup × fuip × total plasma concentration = fut × fuit × total tissue concentration, and, hence, the free drug concentration in plasma and tissue differed by fuip/fuit). Therefore, this assumption should be adjusted for the ionized drugs, and, hence, a mathematical correction to the basic assumption of similar free drug concentration in plasma and tissues can be derived from the tissue composition-based model. Note that this assumption will be further challenged in a dynamic in vivo system in a companion manuscript. Overall, this study was a first attempt to predict the in vivo Kp values for specific human tissues by considering separately the effect of fup and fut , with the aim of facilitating the use of physiologically-based PK (PBPK) model in PK/PD studies.
© 2015 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  ADME; PBPK modeling; PKPD; clinical pharmacokinetics; disposition; distribution; partition coefficients; pharmacokinetics

Mesh:

Substances:

Year:  2015        PMID: 25808270     DOI: 10.1002/jps.24427

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Interethnic scaling of fraction unbound of a drug in plasma and volume of distribution: an analysis of extrapolation from Caucasians to Chinese.

Authors:  Guo Yu; Hong-Hao Zhou; Qing-Shan Zheng; Guo-Fu Li
Journal:  Eur J Clin Pharmacol       Date:  2018-12-19       Impact factor: 2.953

Review 2.  Why 90% of clinical drug development fails and how to improve it?

Authors:  Duxin Sun; Wei Gao; Hongxiang Hu; Simon Zhou
Journal:  Acta Pharm Sin B       Date:  2022-02-11       Impact factor: 14.903

3.  Structure‒tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety.

Authors:  Wei Gao; Hongxiang Hu; Lipeng Dai; Miao He; Hebao Yuan; Huixia Zhang; Jinhui Liao; Bo Wen; Yan Li; Maria Palmisano; Mohamed Dit Mady Traore; Simon Zhou; Duxin Sun
Journal:  Acta Pharm Sin B       Date:  2022-02-23       Impact factor: 14.903

Review 4.  Modeling Pharmacokinetic Natural Product-Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach.

Authors:  Emily J Cox; Dan-Dan Tian; John D Clarke; Allan E Rettie; Jashvant D Unadkat; Kenneth E Thummel; Jeannine S McCune; Mary F Paine
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 5.  Development of physiologically-based pharmacokinetic models for standard of care and newer tuberculosis drugs.

Authors:  Helen Humphries; Lisa Almond; Alexander Berg; Iain Gardner; Oliver Hatley; Xian Pan; Ben Small; Mian Zhang; Masoud Jamei; Klaus Romero
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-10-08

Review 6.  Revolutionizing Therapeutic Drug Monitoring with the Use of Interstitial Fluid and Microneedles Technology.

Authors:  Tony K L Kiang; Sahan A Ranamukhaarachchi; Mary H H Ensom
Journal:  Pharmaceutics       Date:  2017-10-11       Impact factor: 6.321

Review 7.  Bridging the Data Gap From in vitro Toxicity Testing to Chemical Safety Assessment Through Computational Modeling.

Authors:  Qiang Zhang; Jin Li; Alistair Middleton; Sudin Bhattacharya; Rory B Conolly
Journal:  Front Public Health       Date:  2018-09-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.